Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Mise à jour : Il y a 4 ans
Référence : NCT01348919

Femme et Homme

Extrait

The primary objective of the study is to determine the maximum tolerated dose (MTD) of CEP-18770 in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.


Critère d'inclusion

  • Multiple myeloma

Liens